Supply shortages of Pfizer's Jaquinus in Russian market

13 December 2023

Russia has faced a shortage of Jaquinus/Xeljanz (tofacitinib), a drug to treat rheumatoid arthritis from US pharma giant Pfizer (NYSE: PFE), reports The Pharma Letter’s correspondent.

According to some Russian media reports, many of Russian pharmacies are currently selling off the last batches of the drug. The same has been confirmed by representatives of some largest federal clinics in Russia, according to which there have been serious problems with the supplies of the drug for at least four months.

Despite these reports, an official Pfizer spokesman has said that deliveries of Jaquinus to Russian pharmacies are carried out regularly. He recalls that contract production of the original drug has been carried out at the Polisan company in St Petersburg since 2016 and there are sufficient stocks of this drug in warehouses. Moreover, according to him, Pfizer is ready to consider increasing the volume of supplies if necessary. Polisan was not available for comments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK